Biomedicine & Pharmacotherapy
Biomedicine & Pharmacotherapy (Biomed. Pharmacother.) is a biomedical and pharmacology journal published by Elsevier. The present-name entity dates from 1982 and continues the Biomedicine series, and the journal became fully open access in December 2018. It appears in twelve volumes a year and had a 2025 impact factor of 7.5.《生物医学与药物治疗》（Biomedicine & Pharmacotherapy''''，缩写 Biomed. Pharmacother.''）是爱思唯尔出版的生物医学与药理学期刊，现名实体的出版起点为 1982 年，承接前身《生物医学》系列，2018 年 12 月起转为完全开放获取。该刊每年十二卷，二〇二五年影响因子为 7.5。
Scope
The journal's editorial stance is that mechanism and drug should be joined by the thread of disease: a study may be a discovery in basic biomedicine or a preclinical pharmacological validation, but it must sit on the chain of prevention or treatment of a specific disease, and work on natural products must give full compound characterisation with in vitro and in vivo validation. The principal areas are:本刊的取稿立场是「以疾病为线索串起机制与药物」：一项研究既可以是基础生物医学的发现，也可以是临床前的药理验证，但都要落在具体疾病的防治链条上；涉及天然产物的工作须给出充分的化合物表征与体内外验证。收文重点包括：
- Basic biomedicine: disease mechanism and pathway studies, cell and molecular biology, the establishment and validation of animal models, and omics and systems biology.基础生物医学： 疾病机制与通路研究、细胞与分子生物学、动物模型的建立与验证、组学与系统生物学。
- Translational medicine: the bridge from laboratory finding to clinical validation, the discovery and validation of biomarkers, and mechanistic work combining diagnosis with therapy.转化医学： 从实验室发现到临床验证的衔接、生物标志物的发现与验证、诊疗一体化的机制研究。
- Preclinical pharmacology: efficacy and pharmacokinetics of candidates, formulation and delivery systems, target validation, and combination therapy and dosing regimens.临床前药理学： 候选药物的药效与药代、剂型与递送系统、药物靶点验证、联合用药与给药方案。
- Oncology: mechanisms of tumour initiation and progression, resistance and its reversal, targeted and immunotherapy, and the tumour microenvironment and metastasis.肿瘤： 肿瘤发生与进展机制、耐药与逆转策略、靶向与免疫治疗、肿瘤微环境与转移。
- Neurodegenerative disease: Alzheimer and Parkinson disease, neuroinflammation and protein aggregation, and neuroprotection and regenerative strategies.神经退行性疾病： 阿尔茨海默病与帕金森病、神经炎症与蛋白聚集、神经保护与再生策略。
- Cardiovascular, infection and natural products: mechanisms of cardiovascular injury and protection, anti-infective agents and the host response, and the pharmacology of natural products and nutraceuticals.心血管、感染与天然产物： 心血管损伤与保护机制、抗感染药物与宿主应答、天然产物与营养保健品的药理研究。
The journal is now fully open access, with an article processing charge of 3,610 US dollars subject to regional pricing. The publisher reports two days to first decision, forty days to a decision after review and seventy-seven days to acceptance, the first-decision figure including editorial screening.本刊现为完全开放获取，文章处理费为三千六百一十美元并实行地区定价；出版方公布投稿至首次决定两天、复审后决定四十天、投稿至接收七十七天，其中首次决定包含编辑部初筛。[1]
History
- Start of the lineage and of the present name: the journal continues Biomedicine (ISSN 0300-0893) and Biomedicine express (ISSN 0300-0885) with unbroken volume numbering. The NLM catalogue takes volume 36, issue 1 of 1982 as the start of the present-name entity, while the publisher's issue listing, citing a fiftieth-anniversary special issue of 2006, places the start of the lineage in 1956刊脉起点与现名起点： 本刊承接前身《生物医学》（ISSN 0300-0893）与《生物医学快报》（ISSN 0300-0885），卷号续接；NLM 目录以 1982 年第 36 卷第 1 期为现名实体的出版起点，而出版方卷期页据 2006 年的五十周年专刊把脉络起点记为 1956 年，两说并存且未获统一。 the two accounts stand together unreconciled.[2]
- Founders: the publisher's editorial page names Georges Mathé and Haim Tapiero as founding editors, respectively leading figures of French clinical oncology and experimental pharmacology创办人： 出版方编委页列（Georges Mathé）与（Haim Tapiero）为本刊的创刊编辑，两人分别为法国临床肿瘤学与实验药理学的代表人物，本刊早期「实验与临床并举」的取向即源自这一组合。 the journal's early orientation towards experiment and clinic alike comes from that pairing.[3]
- Move to full open access (2018): from 1 December 2018 all papers have appeared open access, the publisher's issue page giving that date as both 1 December and 30 November in different places, an internal inconsistency转为完全开放获取（2018年）： 2018 年 12 月 1 日起本刊全部论文改为开放获取，出版方卷期页在不同位置分别标注该日为 12 月 1 日与 11 月 30 日，官方自身两处不一致；转型后开放获取比例由混合状态升至接近百分之百。 after the change the open access share rose from hybrid levels to nearly one hundred per cent.[2]
- Growth and metrics: the journal ran at one volume a year up to 2014, eight volumes a year from 2015 to 2018 and twelve from 2019, with volumes 182 to 193 in 2025. The impact factor is 7.5 and the CiteScore 15.9, and the journal is indexed in Scopus, MEDLINE and the Science Citation Index Expanded.卷期扩张与指标： 2014 年及以前每年一卷，2015 至 2018 年每年八卷，2019 年起每年十二卷，2025 年为第 182 至 193 卷；影响因子 7.5、引用分数 15.9，本刊被 Scopus、MEDLINE 与科学引文索引扩展版收录。[1]
Editors
The journal is led by an editor-in-chief with a board divided by disease area, whose membership spans basic pharmacology and clinical medicine. The publisher publishes no list of past editors with terms本刊由一名主编主持，下设按疾病方向分工的编委，编委构成兼顾基础药理与临床医学；出版方不公布历任主编的任期表，创刊编辑与现任主编是两端可确证的人选。 the founding editors and the present holder are the two ends that can be established.[3]
- Present editor-in-chief: Danyelle Townsend holds the chair in the Department of Drug Discovery and Biomedical Sciences at the University of South Carolina. The publisher does not state the year of her appointment.现任主编： （Danyelle Townsend）任主编，供职于南卡罗来纳大学药物发现与生物医学科学系；出版方未公布其就任年份。[3]
- Founding editors: Georges Mathé and Haim Tapiero are listed by the publisher as founding editors创刊编辑： （Georges Mathé）与（Haim Tapiero）被出版方列为创刊编辑，两人均已去世；出版方未给出两人的确切任期，也未列出其间的历任主编。 both are now deceased. The publisher gives neither their exact terms nor the editors who served between them and the present holder.[3]
- Role in the field: after its move to full open access the journal became one of the higher-volume open access titles in pharmacology and oncology, and its requirement that natural product work be fully characterised is an explicit threshold set in response to disputes over quality in that area.学科角色： 本刊在转向完全开放获取后成为药理与肿瘤方向投稿量较大的开放获取刊物之一，其要求天然产物研究必须给出充分表征的规定，是针对该方向研究质量争议而设的明确门槛。[4]